CUREVAC N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.33 USD | +0.87% |
|
-4.51% | -44.66% |
| 04-26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
| 04-25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 11,713 | 5,645 | 1,072 | 854.1 | 488.7 | - | - |
| Enterprise Value (EV) 1 | 10,443 | 4,862 | 605 | 854.1 | 488.7 | 395.4 | 488.7 |
| P/E ratio | -67.7 x | -13.7 x | -4.27 x | -3.23 x | -2.6 x | -2.92 x | -3.14 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 240 x | 54.8 x | 15.9 x | 15.9 x | 6.87 x | 4.21 x | 1.89 x |
| EV / Revenue | 240 x | 54.8 x | 15.9 x | 15.9 x | 6.87 x | 4.21 x | 1.89 x |
| EV / EBITDA | -118 x | -7.4 x | -4.75 x | -3.41 x | -2.48 x | -3.14 x | -3.1 x |
| EV / FCF | 24.1 x | -6.58 x | -2.86 x | - | -2.13 x | -3.59 x | -9.77 x |
| FCF Yield | 4.15% | -15.2% | -34.9% | - | -46.9% | -27.8% | -10.2% |
| Price to Book | 12.3 x | 8.2 x | 2.06 x | - | -2.48 x | -0.98 x | -0.53 x |
| Nbr of stocks (in thousands) | 176,460 | 187,050 | 190,244 | 223,924 | 223,924 | - | - |
| Reference price 2 | 66.38 | 30.18 | 5.634 | 3.814 | 2.183 | 2.183 | 2.183 |
| Announcement Date | 21-04-15 | 22-04-28 | 23-04-25 | 24-04-24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.42 | 48.9 | 103 | 67.42 | 53.8 | 71.1 | 116 | 259.2 |
| EBITDA 1 | - | -99.14 | -762.4 | -225.7 | -250.8 | -197.1 | -155.5 | -157.8 |
| EBIT 1 | - | -109.8 | -778.1 | -249.5 | -274.2 | -219.7 | -167.7 | -167 |
| Operating Margin | - | -224.54% | -755.53% | -370% | -509.67% | -309.06% | -144.53% | -64.41% |
| Earnings before Tax (EBT) 1 | - | -129.8 | -412.5 | -249.2 | -260 | -191.9 | -150.2 | -154.6 |
| Net income 1 | - | -129.1 | -411.7 | -249 | -260.2 | -176.4 | -147.2 | -154.4 |
| Net margin | - | -264.05% | -399.76% | -369.37% | -483.58% | -248.07% | -126.87% | -59.57% |
| EPS 2 | -137.4 | -0.9800 | -2.210 | -1.320 | -1.180 | -0.8379 | -0.7466 | -0.6944 |
| Free Cash Flow 1 | - | 486.1 | -857.4 | -374.2 | - | -229 | -136 | -50 |
| FCF margin | - | 994.02% | -832.46% | -555.03% | - | -322.09% | -117.19% | -19.29% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-04-29 | 21-04-15 | 22-04-28 | 23-04-25 | 24-04-24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 29.36 | 41.22 | 24.4 | 20.1 | 11.2 | 11.69 | 7.129 | 7.579 | 16.5 | 22.6 | 15.34 | 15.34 | 17.84 | 17.77 | 3.545 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -143.1 | -371.4 | -15.27 | -60.3 | -52.4 | -121.5 | -60.36 | -71.8 | -54.04 | -88 | -59.97 | -56.39 | -54.51 | -53.75 | -64.8 |
| Operating Margin | -487.15% | -900.84% | -62.57% | -300% | -467.86% | -1,039.52% | -846.61% | -947.37% | -327.49% | -389.38% | -390.99% | -367.65% | -305.58% | -302.39% | -1,827.93% |
| Earnings before Tax (EBT) 1 | - | -4.559 | -15.2 | -57.6 | - | -128.8 | -57.42 | -67.39 | -48.7 | -86.5 | -55 | -52 | -51 | -52 | - |
| Net income 1 | - | -1.936 | -15.09 | -57.58 | - | -128.8 | -57.42 | -67.41 | -48.68 | -86.65 | -43 | -41.5 | -41 | -41.5 | - |
| Net margin | - | -4.7% | -61.86% | -286.49% | - | -1,101.75% | -805.43% | -889.48% | -295.04% | -383.42% | -280.37% | -270.59% | -229.86% | -233.48% | - |
| EPS 2 | - | - | -0.0800 | -0.3100 | -0.2500 | -0.6800 | -0.2700 | -0.3000 | -0.2200 | -0.3900 | -0.2300 | -0.2204 | -0.2163 | -0.2091 | -0.2737 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-12-17 | 22-04-28 | 22-05-25 | 22-08-18 | 22-11-16 | 23-04-25 | 23-05-30 | 23-08-17 | 23-11-14 | 24-04-24 | - | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 1,270 | 783 | 467 | - | - | 93.3 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 486 | -857 | -374 | - | -229 | -136 | -50 |
| ROE (net income / shareholders' equity) | - | -38.6% | -58.8% | -40.8% | - | -65.6% | -101% | -85.3% |
| ROA (Net income/ Total Assets) | - | - | -30.8% | -24.7% | - | -41.9% | -34% | -9.95% |
| Assets 1 | - | - | 1,335 | 1,009 | - | 421.1 | 433 | 1,553 |
| Book Value Per Share 2 | - | 5.380 | 3.680 | 2.740 | - | -0.8800 | -2.240 | -4.130 |
| Cash Flow per Share 2 | - | 3.950 | -3.940 | -1.510 | - | -1.040 | -0.7600 | -0.8600 |
| Capex 1 | - | 36.3 | 124 | 88 | - | 83.2 | 61.5 | 63.9 |
| Capex / Sales | - | 74.29% | 120.62% | 130.56% | - | 117.03% | 53.02% | 24.67% |
| Announcement Date | 20-04-29 | 21-04-15 | 22-04-28 | 23-04-25 | 24-04-24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.183
EUR
Average target price
12.89
EUR
Spread / Average Target
+490.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.66% | 522M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CVAC Stock
- Financials CureVac N.V.
